Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
LMAT's Cash to Debt is ranked higher than
90% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. LMAT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
LMAT' s 10-Year Cash to Debt Range
Min: 0.1  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.85
LMAT's Equity to Asset is ranked higher than
88% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. LMAT: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
LMAT' s 10-Year Equity to Asset Range
Min: 0.4  Med: 0.84 Max: 0.9
Current: 0.85
0.4
0.9
Interest Coverage 1268.00
LMAT's Interest Coverage is ranked higher than
62% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 38.48 vs. LMAT: 1268.00 )
Ranked among companies with meaningful Interest Coverage only.
LMAT' s 10-Year Interest Coverage Range
Min: 2.32  Med: 589.75 Max: 9999.99
Current: 1268
2.32
9999.99
F-Score: 8
Z-Score: 14.44
M-Score: -2.37
WACC vs ROIC
3.25%
11.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.12
LMAT's Operating margin (%) is ranked higher than
65% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. LMAT: 12.12 )
Ranked among companies with meaningful Operating margin (%) only.
LMAT' s 10-Year Operating margin (%) Range
Min: -10.33  Med: 4.42 Max: 8.92
Current: 12.12
-10.33
8.92
Net-margin (%) 7.49
LMAT's Net-margin (%) is ranked higher than
61% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.58 vs. LMAT: 7.49 )
Ranked among companies with meaningful Net-margin (%) only.
LMAT' s 10-Year Net-margin (%) Range
Min: -7.08  Med: 2.96 Max: 10.73
Current: 7.49
-7.08
10.73
ROE (%) 8.39
LMAT's ROE (%) is ranked higher than
58% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. LMAT: 8.39 )
Ranked among companies with meaningful ROE (%) only.
LMAT' s 10-Year ROE (%) Range
Min: -7.03  Med: 4.10 Max: 12.52
Current: 8.39
-7.03
12.52
ROA (%) 6.97
LMAT's ROA (%) is ranked higher than
71% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. LMAT: 6.97 )
Ranked among companies with meaningful ROA (%) only.
LMAT' s 10-Year ROA (%) Range
Min: -5.75  Med: 3.49 Max: 10.01
Current: 6.97
-5.75
10.01
ROC (Joel Greenblatt) (%) 33.66
LMAT's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. LMAT: 33.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LMAT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -24.38  Med: 21.42 Max: 68.89
Current: 33.66
-24.38
68.89
Revenue Growth (3Y)(%) 5.00
LMAT's Revenue Growth (3Y)(%) is ranked higher than
50% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. LMAT: 5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LMAT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.9  Med: 5.00 Max: 21.4
Current: 5
-4.9
21.4
EBITDA Growth (3Y)(%) 16.60
LMAT's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. LMAT: 16.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LMAT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 17.30 Max: 27.9
Current: 16.6
0
27.9
EPS Growth (3Y)(%) 20.90
LMAT's EPS Growth (3Y)(%) is ranked higher than
74% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. LMAT: 20.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LMAT' s 10-Year EPS Growth (3Y)(%) Range
Min: -45  Med: 17.00 Max: 44.2
Current: 20.9
-45
44.2
» LMAT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

LMAT Guru Trades in Q2 2014

Jim Simons 20,262 sh (+52.60%)
» More
Q3 2014

LMAT Guru Trades in Q3 2014

Jim Simons 27,400 sh (+35.23%)
» More
Q4 2014

LMAT Guru Trades in Q4 2014

Jim Simons 43,063 sh (+57.16%)
» More
Q1 2015

LMAT Guru Trades in Q1 2015

Chuck Royce 9,900 sh (New)
Jim Simons 52,600 sh (+22.15%)
» More
» Details

Insider Trades

Latest Guru Trades with LMAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 44.78
LMAT's P/E(ttm) is ranked lower than
61% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.30 vs. LMAT: 44.78 )
Ranked among companies with meaningful P/E(ttm) only.
LMAT' s 10-Year P/E(ttm) Range
Min: 15.99  Med: 34.87 Max: 125
Current: 44.78
15.99
125
Forward P/E 35.59
LMAT's Forward P/E is ranked lower than
80% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.03 vs. LMAT: 35.59 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 39.90
LMAT's PE(NRI) is ranked lower than
63% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.10 vs. LMAT: 39.90 )
Ranked among companies with meaningful PE(NRI) only.
LMAT' s 10-Year PE(NRI) Range
Min: 15.93  Med: 35.26 Max: 125
Current: 39.9
15.93
125
P/B 3.65
LMAT's P/B is ranked lower than
51% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.81 vs. LMAT: 3.65 )
Ranked among companies with meaningful P/B only.
LMAT' s 10-Year P/B Range
Min: 0.67  Med: 1.83 Max: 3.65
Current: 3.65
0.67
3.65
P/S 3.41
LMAT's P/S is ranked higher than
51% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. LMAT: 3.41 )
Ranked among companies with meaningful P/S only.
LMAT' s 10-Year P/S Range
Min: 0.63  Med: 1.74 Max: 3.41
Current: 3.41
0.63
3.41
PFCF 44.51
LMAT's PFCF is ranked lower than
61% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.93 vs. LMAT: 44.51 )
Ranked among companies with meaningful PFCF only.
LMAT' s 10-Year PFCF Range
Min: 9.1  Med: 39.06 Max: 116.17
Current: 44.51
9.1
116.17
POCF 37.46
LMAT's POCF is ranked lower than
71% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.33 vs. LMAT: 37.46 )
Ranked among companies with meaningful POCF only.
LMAT' s 10-Year POCF Range
Min: 8.42  Med: 23.04 Max: 76.33
Current: 37.46
8.42
76.33
EV-to-EBIT 28.20
LMAT's EV-to-EBIT is ranked higher than
54% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.92 vs. LMAT: 28.20 )
Ranked among companies with meaningful EV-to-EBIT only.
LMAT' s 10-Year EV-to-EBIT Range
Min: -831.4  Med: 17.70 Max: 61.8
Current: 28.2
-831.4
61.8
PEG 2.35
LMAT's PEG is ranked higher than
62% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. LMAT: 2.35 )
Ranked among companies with meaningful PEG only.
LMAT' s 10-Year PEG Range
Min: 2.11  Med: 3.30 Max: 4.78
Current: 2.35
2.11
4.78
Shiller P/E 56.09
LMAT's Shiller P/E is ranked lower than
71% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.27 vs. LMAT: 56.09 )
Ranked among companies with meaningful Shiller P/E only.
LMAT' s 10-Year Shiller P/E Range
Min: 31.16  Med: 61.54 Max: 162.5
Current: 56.09
31.16
162.5
Current Ratio 5.70
LMAT's Current Ratio is ranked higher than
86% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. LMAT: 5.70 )
Ranked among companies with meaningful Current Ratio only.
LMAT' s 10-Year Current Ratio Range
Min: 1.39  Med: 5.15 Max: 8.76
Current: 5.7
1.39
8.76
Quick Ratio 3.74
LMAT's Quick Ratio is ranked higher than
76% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. LMAT: 3.74 )
Ranked among companies with meaningful Quick Ratio only.
LMAT' s 10-Year Quick Ratio Range
Min: 0.73  Med: 3.89 Max: 7.26
Current: 3.74
0.73
7.26
Days Inventory 251.99
LMAT's Days Inventory is ranked lower than
86% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.78 vs. LMAT: 251.99 )
Ranked among companies with meaningful Days Inventory only.
LMAT' s 10-Year Days Inventory Range
Min: 76.75  Med: 203.82 Max: 266.3
Current: 251.99
76.75
266.3
Days Sales Outstanding 59.15
LMAT's Days Sales Outstanding is ranked higher than
53% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. LMAT: 59.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
LMAT' s 10-Year Days Sales Outstanding Range
Min: 48.86  Med: 55.18 Max: 61.82
Current: 59.15
48.86
61.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.05
LMAT's Dividend Yield is ranked lower than
55% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. LMAT: 1.05 )
Ranked among companies with meaningful Dividend Yield only.
LMAT' s 10-Year Dividend Yield Range
Min: 0.28  Med: 1.55 Max: 1.98
Current: 1.05
0.28
1.98
Dividend Payout 0.46
LMAT's Dividend Payout is ranked lower than
69% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.38 vs. LMAT: 0.46 )
Ranked among companies with meaningful Dividend Payout only.
LMAT' s 10-Year Dividend Payout Range
Min: 0.25  Med: 0.60 Max: 1.25
Current: 0.46
0.25
1.25
Dividend growth (3y) 20.50
LMAT's Dividend growth (3y) is ranked higher than
81% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.10 vs. LMAT: 20.50 )
Ranked among companies with meaningful Dividend growth (3y) only.
LMAT' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 20.5
Current: 20.5
0
20.5
Yield on cost (5-Year) 1.04
LMAT's Yield on cost (5-Year) is ranked lower than
63% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. LMAT: 1.04 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
LMAT' s 10-Year Yield on cost (5-Year) Range
Min: 0.28  Med: 1.55 Max: 1.98
Current: 1.04
0.28
1.98
Share Buyback Rate -2.10
LMAT's Share Buyback Rate is ranked higher than
52% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.40 vs. LMAT: -2.10 )
Ranked among companies with meaningful Share Buyback Rate only.
LMAT' s 10-Year Share Buyback Rate Range
Min: 0.7  Med: -4.20 Max: -22.6
Current: -2.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 45.94
LMAT's Price/Net Cash is ranked lower than
70% of the 43 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.27 vs. LMAT: 45.94 )
Ranked among companies with meaningful Price/Net Cash only.
LMAT' s 10-Year Price/Net Cash Range
Min: 2.85  Med: 7.27 Max: 160.2
Current: 45.94
2.85
160.2
Price/Net Current Asset Value 6.91
LMAT's Price/Net Current Asset Value is ranked higher than
62% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.86 vs. LMAT: 6.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LMAT' s 10-Year Price/Net Current Asset Value Range
Min: 1.27  Med: 2.95 Max: 4.51
Current: 6.91
1.27
4.51
Price/Tangible Book 5.65
LMAT's Price/Tangible Book is ranked lower than
52% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. LMAT: 5.65 )
Ranked among companies with meaningful Price/Tangible Book only.
LMAT' s 10-Year Price/Tangible Book Range
Min: 1.13  Med: 2.58 Max: 3.54
Current: 5.65
1.13
3.54
Price/Projected FCF 2.84
LMAT's Price/Projected FCF is ranked lower than
67% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.76 vs. LMAT: 2.84 )
Ranked among companies with meaningful Price/Projected FCF only.
LMAT' s 10-Year Price/Projected FCF Range
Min: 1.42  Med: 1.80 Max: 2.56
Current: 2.84
1.42
2.56
Price/Median PS Value 1.95
LMAT's Price/Median PS Value is ranked lower than
70% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. LMAT: 1.95 )
Ranked among companies with meaningful Price/Median PS Value only.
LMAT' s 10-Year Price/Median PS Value Range
Min: 0.43  Med: 0.98 Max: 1.69
Current: 1.95
0.43
1.69
Price/Peter Lynch Fair Value 3.85
LMAT's Price/Peter Lynch Fair Value is ranked lower than
73% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. LMAT: 3.85 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LMAT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 2.26  Med: 3.74 Max: 4.47
Current: 3.85
2.26
4.47
Price/Graham Number 3.37
LMAT's Price/Graham Number is ranked lower than
57% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. LMAT: 3.37 )
Ranked among companies with meaningful Price/Graham Number only.
LMAT' s 10-Year Price/Graham Number Range
Min: 1.19  Med: 1.99 Max: 3.03
Current: 3.37
1.19
3.03
Earnings Yield (Greenblatt) (%) 3.59
LMAT's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. LMAT: 3.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LMAT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.6  Med: 4.90 Max: 10.1
Current: 3.59
1.6
10.1
Forward Rate of Return (Yacktman) (%) 12.91
LMAT's Forward Rate of Return (Yacktman) (%) is ranked higher than
56% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.07 vs. LMAT: 12.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LMAT' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -2.3  Med: 2.30 Max: 26.1
Current: 12.91
-2.3
26.1

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
LeMaitre Vascular Inc was incorporated in Massachusetts on November 28, 1983, as Vascutech, Inc. On April 6, 2001, the Company changed its name to LeMaitre Vascular, Inc. The Company is a provider of medical devices and implants for the treatment of peripheral vascular disease. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons. Its diversified portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and are well known to vascular surgeons, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch. Its products are used by vascular surgeons who treat peripheral vascular disease through both open surgical methods and endovascular techniques. In contrast to interventional cardiologists and interventional radiologists, neither of whom are certified to perform open surgical procedures, vascular surgeons can perform both open surgical and minimally invasive endovascular procedures, and are therefore positioned to provide treatment options to patients. The principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. It has completed fourteen acquisitions of complementary products since 1998. The Company also sells non-vascular medical devices used in general surgery procedures, primarily laparoscopic cholecystectomy. Its leading general surgery product is the Reddick Cholangiogram Catheter, which is used to inject dye into the cystic duct during laparoscopic cholecystectomy. In this procedure, the gall bladder is dissected and removed through small punctures in the abdomen. It also offers two laparoscopic accessories used in laparoscopic gall bladder removal. Notable competitors of the Company include Applied Medical Resources Corporation, Baxter International, Inc., Cardiovascular Systems, Inc., C.R. Bard, Inc., Edwards Lifesciences Corporation, Getinge AB, Jotec GmbH, SAS Perouse Medical, Terumo Medical Corporation, Uresil, LLC, and W. L. Gore & Associates. It relies on a combination of patents, trademarks, trade secret laws, and confidentiality and invention assignment agreements to protect its intellectual property rights. The products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (the FDCA).
» More Articles for LMAT

Headlines

Articles On GuruFocus.com
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 10 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Aug 12 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) May 13 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 13 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,500 Shares Jun 05 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,250 Shares May 28 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,000 Shares May 18 2009 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) May 14 2009 

More From Other Websites
LeMaitre posts 2Q profit Jul 28 2015
LeMaitre posts 2Q profit Jul 28 2015
LeMaitre Vascular Inc Earnings Call scheduled for 5:00 pm ET today Jul 28 2015
LeMaitre Q2 2015 Record Sales $19.9mm (+12% organic), Record Op. Inc. $2.8mm (+41%) Jul 28 2015
LEMAITRE VASCULAR INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 28 2015
LeMaitre Q2 2015 Record Sales $19.9mm (+12% organic), Record Op. Inc. $2.8mm (+41%) Jul 28 2015
Q2 2015 LeMaitre Vascular Inc Earnings Release - After Market Close Jul 28 2015
LeMaitre Vascular to Present at Three Investor Conferences in August Jul 20 2015
LeMaitre Vascular to Present at Three Investor Conferences in August Jul 20 2015
LeMaitre Vascular Will Announce Second Quarter 2015 Earnings Results on July 28, 2015 Jul 15 2015
LeMaitre Vascular Will Announce Second Quarter 2015 Earnings Results on July 28, 2015 Jul 15 2015
LeMaitre Vascular Announces Analyst Day, Thursday, December 3, 2015 Jul 09 2015
LeMaitre Vascular Announces Analyst Day, Thursday, December 3, 2015 Jul 09 2015
LeMaitre Continues to Expand Direct-to-Hospital Sales Jun 30 2015
LeMaitre Continues to Expand Direct-to-Hospital Sales Jun 30 2015
Coverage initiated on Lemaitre Vascular by Dougherty & Company Jun 19 2015
LeMaitre Vascular Set to Join Russell 2000 Index Jun 17 2015
LeMaitre Vascular Set to Join Russell 2000 Index Jun 17 2015
LEMAITRE VASCULAR INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 08 2015
LeMaitre Hits 52-Week High on Solid Q1 & Pipeline Strength - Analyst Blog Jun 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK